(Total Views: 507)
Posted On: 04/11/2020 7:14:08 AM
Post# of 153981
That is very interesting... thank you.
Agreed, if the studies come back positive, they will be proof-of-concept studies for ARDS syndrom and other (auto)immune diseases in general, and thus validate leronlimab in these areas. That would be HUGE.
But the lack of decisive action of the regulatory bodies even during such crises is lame and unnecessary. Pick the safest treatments with an extensive safety database whose MOA have either shown promise or are reasonably likely to offer benefit, approve them, and study them in the real world.
Agreed, if the studies come back positive, they will be proof-of-concept studies for ARDS syndrom and other (auto)immune diseases in general, and thus validate leronlimab in these areas. That would be HUGE.
But the lack of decisive action of the regulatory bodies even during such crises is lame and unnecessary. Pick the safest treatments with an extensive safety database whose MOA have either shown promise or are reasonably likely to offer benefit, approve them, and study them in the real world.
(0)
(0)
